A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation

PharmacoEconomics

Volumn 31, Issue 7, 2013, Pages 589-604

  Sorensen, Sonja V ^a   Peng, Siyang ^a   Monz, Brigitta U ^b   Bradley Kennedy, Carole ^c   Kansal, Anuraag R ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC EVALUATION; ECONOMIC MODEL; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MODEL; PRIORITY JOURNAL; QUALITY OF LIFE; REPRODUCIBILITY; REVIEW; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; UNITED STATES;

ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; STROKE; WARFARIN;

EID: 84879928891     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0035-8     Document Type: Review

References (33)

1. National Institute for Health and Clinical Excellence (NICE). Costing report: implementing NICE guidance in England. Atrial fibrillation: the management of atrial fibrillation. NICE clinical guideline 36. London: National Institute for Health and Clinical Excellence; 2006.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-5.
3. Luengo-Fernandez R, Yiin GS, Gray AM, et al. Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke. 2012. doi: 10.1111/j.1747-4949.2012.00812.x.
4. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-220.
5. National Institute for Health and Clinical Excellence (NICE). Atrial fibrillation - dabigatran etexilate (TA249). Final guidance [NICE technology appraisal guidance no. 249; online]. London: National Institute for Health and Clinical Excellence; 2012. http://www.nice.org.uk/ta249. Accessed 19 Mar 2012.
6. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125-36.
7. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2011;8(3):e1-8.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875-6.
10. Canadian Agency for Drugs and Technology in Health (CADTH). CEDAC final recommendation: dabigatran etexilate. In: New indication: prevention of stroke and systemic embolism in patients with atrial fibrillation. Ottawa: Canadian Agency for Drugs and Technology in Health (CADTH).
11. Pharmaceutical Benefits Advisory Committee (PBAC). Public summary document: dabigatran etexilate. Department of Health and Ageing, Australian Government. Australia: Canberra; 2011.
12. Scottish Medicines Consortium. Dabigatran etexilate 110 mg and 150 mg hard capsules (Pradaxa®). 12 September 2011. Report no.: SMC No. (672/11) Scotland: Glasgow.
13. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1-11.
14. Kamel H, Johnston SC, Easton JD, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012;43(3):881-3.
15. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562-70.
16. Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98(7):573-8.
17. Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333.
18. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105(5):908-19.
19. Langkilde LK, Bergholdt Asmussen M, Overgaard M. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J Med Econ. 2012;15(4):695-703.
20. Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-56.
21. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437-52.
22. Clarke LD, Plevritis SK, Boer R, et al. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr. 2006;36:96-105.
23. Boehringer Ingelheim Pharmaceuticals Inc. Advisory committee briefing document - dabigatran etexilate. Food and Drug Administration, 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf). Accessed 18 April 2012.
24. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164(8):880-4.
25. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm. 2008;5(10):1365-72.
26. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-83.
27. Bamford J, Sandercock P, Dennis M, et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project-1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1990;53(1):16-22.
28. McKeage K. Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Pharmacoeconomics. 2012;30(9):841-55.
29. Reddy P, Atay JK, Selbovitz LG, et al. Dabigatran: a review of clinical and pharmacoeconomic evidence. Crit Pathw Cardiol. 2011;10(3):117-27.
30. Solomon MD, Ullal AJ, Hoang DD, et al. Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. J Cardiovasc Med (Hagerstown). 2012;13(2):86-96.
31. Canadian Agency for Drugs and Technology in Health (CADTH). New oral anticoagulants for the prevention of thromboembolic events in patients with atrial fibrillation. Ottawa: Canadian Agency for Drugs and Technology in Health (CADTH); 2012.
32. Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost. 2012;108(4):672-82.
33. Freeman J, Turakhia M. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation (Author reply). Ann Intern Med. 2011;154(8):570-1.